VSee Health Reports Third Quarter 2024 Revenue Up 131% Year-over-Year

VSee Health, Inc. (Nasdaq: VSEE), a provider of comprehensive telehealth services that customize workflow streams and enhance patient care, today provided a business update and reported financial results for the three and nine months ended September 30, 2024.

Financial & Business Highlights

• Revenue was $3.4 million for the third quarter of 2024, up 131% over the third quarter of 2023.
• Revenue was $6.6 million for the nine months ended September 30, 2024, up 51% over the nine months ended September 30, 2023.
• Contracted with Seven Corners Correctional Health, the operator of 24 federal prisons, to offer accessible, quality specialty care to the inmate population they serve.
• Expanded our telehealth and billing services to major healthcare clients through a partnership with SkywardRx, including nonprofit, hospital and Fortune 20 corporate clients.
• Partnered with Ava Robotics for the development of a VSee Health-powered Ava robot that allows providers to extend their reach and provide personalized care remotely to hospital intensive care units.
• Launched Aimee, an innovative virtual healthcare, labs and prescription drug service that patients can access whether or not they have health insurance, providing low-cost access to quality healthcare.
• Launched a sea ambulance telehealth initiative utilizing Starlink satellite technology, providing US veterans and residents in remote areas with access to virtual doctor consultations and emergency care.
• Introduced a GLP-1 telehealth program to address obesity and chronic diseases, integrating prescription medication, personalized care plans, and behavioral interventions to provide affordable, impactful healthcare solutions for underserved communities.
• Partnered with BabyLiveAdvice to address maternal care disparities by launching an innovative virtual maternal care model to provide comprehensive care for underserved communities.

Management Commentary

"This quarter marks a transformative moment for VSee Health, the completion of our first full quarter post-merger. The integration of VSee Lab and iDoc Virtual Telehealth Solutions has solidified our position in delivering scalable, tailored telehealth solutions," said Imo Aisiku, M.D., co-CEO and Chairman of VSee Health. "We believe our combined company is uniquely positioned to address critical challenges in healthcare, from expanding access in underserved communities to optimizing workflows for enterprise-level clients. This period has demonstrated the resilience of our platform and our capacity to drive meaningful impact."

"We believe that our ability to combine fast customization, enterprise scalability, and robust security is what sets us apart in the crowded telehealth space. This quarter’s strategic initiatives and partnerships, including the launch of programs addressing obesity, maternal health disparities, and veteran care, exemplify our commitment to delivering scalable solutions that improve lives while creating long-term value for our stakeholders,” added Milton Chen, Ph.D., co-CEO of VSee Health.

Third Quarter Financial Results

Third quarter consolidated financial statements include the accounts of VSee Health, Inc. and its subsidiaries, VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc., which are both 100% wholly owned subsidiaries of VSee Health following the business combination on June 24, 2024.

Revenue was $3.4 million for the third quarter of 2024, compared to $1.5 million for the third quarter of 2023, an increase of 131%. The increase was primarily driven by $1.1 million or 100% of revenue from the acquisition of iDoc in the second quarter, as well as higher technical and engineering fees, and professional and other fees and. Technical and engineering fees increased by 267% due to a higher volume of engineering, customizations and integration services provided to the U.S. Department of Health and Human Services and existing customers. Professional and other fees increased by 40% due to higher project management services primarily to a recently signed significant client. Subscription revenue also increased 9% due to higher usage volumes.

Operating expenses for the third quarter of 2024 increased by $58.2 million. The increase was driven by one-time goodwill impairment charges of $55.0 million. The increase was also driven by higher general and administrative expense, primarily from amortization expense and an increase in expenses related to the acquisition of iDoc, as well as transaction related expenses from the recapitalization and acquisitions of DHAC and iDoc, primarily for professional and advisory service fees.

Net loss for the third quarter of 2024 was $51.8 million, compared to a net loss of $0.1 million for the third quarter of 2023. The increase was primarily driven by one-time goodwill impairment charges of $55.0 million, and a $0.7 million loss on extinguishment related to note conversions and shares issued to vendors. These were partially offset by a $5.7 million gain on the change in fair value of debt and derivative financial instruments.

Nine Month Financial Results

Revenue was $6.6 million for the nine months ended September 30, 2024, compared to $4.3 million for the nine months ended September 30, 2023, an increase of $2.2 million or 51%. The increase was primarily driven by 100% of revenue from the acquisition of iDoc in the second quarter, as well as higher technical and engineering fees, and professional and other fees. Technical and engineering fees increased by 161% due to a higher volume of customizations, engineering, and integration services for a recently signed significant client and existing customers. Professional and other fees increased by 50% due to increased project management services, higher patient visits, and higher hardware purchases from new customers during the second quarter. These increases were offset by a 2% decline in subscription revenue due to the churned enterprise customers in 2024, as some clients gradually shifted back to face-to-face consultations.

Operating expenses for the nine months ended September 30, 2024 increased by $58.6 million to $63.0 million. The increase was driven by one-time goodwill impairment charges of $55.0 million, as well as higher general and administrative expenses, primarily from amortization expense and an increase of expenses related to the acquisition of iDoc. Additionally, transaction expenses from the recapitalization and acquisitions of DHAC and iDoc contributed to the increase, primarily for professional and advisory service fees.

Net loss for the nine months ended September 30, 2024, was $52.1 million, compared to a net loss of $1.0 million for the same period in 2023. The increase was primarily driven by one-time goodwill impairment charges of $55.0 million, $1.6 million initial fair value loss on the Quantum Note, and $0.7 million loss on extinguishment related to note conversions and shares issued to vendors. These were partially offset by a $6.3 million gain on the change in fair value of debt and derivative financial instruments.

As of September 30, 2024, VSee Health had cash of $2.3 million.

Pro Forma Financial Results

The unaudited pro forma financial information in the tables below summarizes the combined results of VSee Health’s operations and iDoc’s operations, as though the acquisition of iDoc had been completed as of the beginning of 2023.

Proforma total revenues for the third quarter of 2024 were $3.4 million compared with $3.1 million for the third quarter of 2023. Proforma total revenues for the nine months ended September 30, 2024, were $9.2 million compared with $9.4 million for the same period of 2023.

The proforma net loss for the third quarter of 2024 was $0.4 million, or $(0.02) per share, compared with a net loss of $1.3 million, or $(0.09) per share, for the third quarter of 2023. The proforma net loss for the nine months ended September 30, 2024, was $2.4 million, or $(0.16) per share, compared with a net loss of $3.4 million, or $(0.24) per share, for the same period of 2023.

The following table summarizes the pro forma financial information:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended September 30,

 

For the Nine Months Ended September 30,

 

 

2024

 

2023

 

2024

 

2023

Total revenues

 

$

3,354,437

 

$

3,076,235

 

$

9,191,682

 

$

9,390,435

Net loss

 

$

(368,063)

 

$

(1,322,199)

 

$

(2,436,877)

 

$

(3,435,940)

Weighted average shares:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

15,077,548

 

 

14,806,820

 

 

14,821,999

 

 

14,602,506

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.02)

 

$

(0.09)

 

$

(0.16)

 

$

(0.24)

About VSee Health

VSee Health’s AI telehealth platform is the fastest way for enterprises to go from ideation to market go-live. Field-hardened on over 1.5M HIPAA-compliant video encounters every month, its customizable telehealth building blocks each meet stringent security standards, and are ready to scale. VSee Health has deployed services in over 50 countries, including Iraq, Syria, Marshall Islands and El Salvador. Its clients include NASA Space Station, US Department of Health and Human Services, McKesson, Magellan, DaVita, GE, countless startups, and the entire country of Qatar.

VSee Health also provides tailored solutions for critical shortage areas such as critical care and teleradiology. It is committed to empowering high quality healthcare access and reducing physician burnout and workforce shortages through its telehealth technology. For more information, please visit www.vseehealth.com.

Forward-Looking Statements

Matters discussed in this news release that are not statements of historical or current facts, including but not limited to those relating to VSee Health’s ability to improve healthcare access and provider efficiencies, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause performance or achievements to be materially different from historical results or from any future performance or achievements expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. More information on risk factors relating to VSee Health and its technology and billing services is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of VSee Health’s periodic and current filings with the SEC, which are also made available on VSee Health’s website at www.vseehealth.com. Forward-looking statements speak only as of the date they are made, and VSee Health undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, or otherwise

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

 

 

 

 

 

 

September 30,

 

December 31,

 

 

2024

 

2023

 

 

(Unaudited)

 

 

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash

 

$

2,327,337

 

$

118,734

Accounts receivable, net of allowance for credit losses of $2,062,444 and $32,457 as of September 30, 2024, and December 31, 2023, respectively

 

 

2,613,327

 

 

628,480

Due from related party

 

 

560,380

 

 

—

Prepaids and other current assets

 

 

1,606,469

 

 

79,920

Total current assets

 

 

7,107,513

 

 

827,134

 

 

 

 

 

 

 

Note receivable, related party

 

 

245,500

 

 

—

Right-of-use assets, net

 

 

417,835

 

 

—

Intangible assets, net

 

 

11,547,500

 

 

—

Goodwill

 

 

4,916,694

 

 

—

Fixed assets, net

 

 

794,688

 

 

3,657

Total assets

 

$

25,029,730

 

$

830,791

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

8,270,393

 

$

1,824,408

Deferred revenue

 

 

683,111

 

 

802,524

Due to related party

 

 

456,858

 

 

338,506

Operating lease liability

 

 

68,958

 

 

—

Financing lease liability

 

 

191,330

 

 

—

Factoring payable

 

 

208,788

 

 

—

Encompass Purchase liability

 

 

265,978

 

 

—

Income tax payable

 

 

63,855

 

 

—

SAFE Note

 

 

—

 

 

135,000

Contingent liability

 

 

—

 

 

600,000

ELOC

 

 

177,000

 

 

—

ELOC Commitment Fee Note

 

 

495,000

 

 

—

Additional Bridge Notes

 

 

122,000

 

 

—

Exchange Note

 

 

1,851,000

 

 

—

Quantum Convertible Note, related party

 

 

2,985,000

 

 

—

September 2024 Convertible Note

 

 

2,000,000

 

 

—

Loan payable, related party, net of discount

 

 

471,651

 

 

323,000

Line of credit

 

 

456,097

 

 

—

Notes payable, net of discount

 

 

439,183

 

 

220,000

Total current liabilities

 

 

19,206,202

 

 

4,243,438

 

 

 

 

 

 

 

Notes payable, less current portion, net of discount

 

 

593,941

 

 

—

Operating lease liability, less current portion

 

 

289,263

 

 

—

Financing lease liability, less current portion

 

 

181,312

 

 

—

Total liabilities

 

 

20,270,718

 

 

4,243,438

 

 

 

 

 

 

 

Commitments, Contingencies, and Concentration Risk (Note 9)

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity (deficit)

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 6,158 and 0 shares issued and outstanding as of September 30, 2024, and December 31, 2023, respectively

 

 

1

 

 

—

Common stock, $0.0001 par value; 100,000,000 shares authorized 15,362,278 and 4,639,643 shares issued and outstanding as of September 30, 2024, and December 31, 2023, respectively

 

 

1,536

 

 

464

Additional paid-in capital

 

 

66,282,056

 

 

6,027,153

Accumulated deficit

 

 

(61,524,581)

 

 

(9,114,985)

Non-controlling interest

 

 

—

 

 

(325,279)

Total stockholders’ equity (deficit)

 

 

4,759,012

 

 

(3,412,647)

Total liabilities and stockholders’ equity (deficit)

 

$

25,029,730

 

$

830,791

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024, AND 2023 (UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended September 30,

 

For the Nine Months Ended September 30,

 

 

2024

 

2023

 

2024

 

2023

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

Subscription fees

 

$

1,037,457

 

$

947,525

 

$

3,080,085

 

$

3,131,347

Professional services and other fees

 

 

396,455

 

 

283,968

 

 

1,145,930

 

 

762,300

Technical engineering fees

 

 

806,456

 

 

219,978

 

 

1,159,345

 

 

444,315

Patient fees

 

 

623,198

 

 

—

 

 

654,718

 

 

—

Telehealth fees

 

 

485,971

 

 

—

 

 

516,540

 

 

—

Institutional fees

 

 

4,900

 

 

—

 

 

5,380

 

 

—

Total revenues

 

 

3,354,437

 

 

1,451,471

 

 

6,561,998

 

 

4,337,962

Cost of goods sold

 

 

941,388

 

 

478,399

 

 

1,814,281

 

 

1,528,008

Gross margin

 

 

2,413,049

 

 

973,072

 

 

4,747,717

 

 

2,809,954

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Compensation and related benefits

 

 

1,678,627

 

 

1,013,488

 

 

3,490,615

 

 

3,433,658

General and administrative

 

 

2,170,217

 

 

224,874

 

 

2,830,615

 

 

832,513

Goodwill impairment charges

 

 

54,984,000

 

 

—

 

 

54,984,000

 

 

—

Transaction expenses

 

 

646,303

 

 

9,066

 

 

1,653,448

 

 

66,411

Total operating expenses

 

 

59,479,147

 

 

1,247,428

 

 

62,958,678

 

 

4,332,582

 

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss

 

 

(57,066,098)

 

 

(274,356)

 

 

(58,210,961)

 

 

(1,522,628)

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(232,082)

 

 

(36,312)

 

 

(591,087)

 

 

(163,574)

Other income (expense)

 

 

(2)

 

 

—

 

 

—

 

 

19,619

Change in fair value of financial instruments

 

 

5,737,606

 

 

(21,629)

 

 

6,285,706

 

 

92,448

Loss on issuance of financial instruments

 

 

—

 

 

—

 

 

(1,618,234)

 

 

—

Loss on extinguishment

 

 

(740,979)

 

 

—

 

 

(740,979)

 

 

—

Total other income (expense)

 

 

4,764,543

 

 

(57,941)

 

 

3,335,406

 

 

(51,507)

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before benefit from income taxes

 

 

(52,301,555)

 

 

(332,297)

 

 

(54,875,555)

 

 

(1,574,135)

 

 

 

 

 

 

 

 

 

 

 

 

 

Benefit from income taxes

 

 

550,030

 

 

233,716

 

 

2,791,238

 

 

590,954

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(51,751,525)

 

 

(98,581)

 

 

(52,084,317)

 

 

(983,181)

Net profit attributable to non-controlling interest

 

 

—

 

 

12,465

 

 

—

 

 

3,727

Net loss attributable to stockholders

 

 

(51,751,525)

 

 

(111,046)

 

 

(52,084,317)

 

 

(986,908)

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$

(3.43)

 

$

(0.01)

 

$

(6.24)

 

$

(0.10)

Weighted average number of common shares outstanding, basic and diluted

 

 

15,077,548

 

 

9,998,446

 

 

8,351,249

 

 

9,998,446

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

For the Nine Months Ended September 30, 2024 and 2023

 

 

 

 

 

 

 

 

 

For the Nine Months Ended September 30,

 

 

2024

 

2023

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(52,084,317)

 

$

(983,181)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Goodwill impairment charges

 

 

54,984,000

 

 

—

Loss on extinguishment

 

 

740,979

 

 

—

Shares issued as part of stock grants to vendors

 

 

98,000

 

 

—

Loss on issuance of financial instrument

 

 

1,618,234

 

 

—

Original issue discount and interest accrued on Quantum Convertible Note

 

 

395,671

 

 

—

Change in fair value of financial instruments

 

 

(6,285,706)

 

 

(92,448)

Amortization of discount on note payable

 

 

7,000

 

 

93,000

Amortization of right-of-use assets

 

 

17,209

 

 

—

Stock-based compensation

 

 

381,084

 

 

—

Depreciation and amortization

 

 

651,761

 

 

395

Allowance for expected credit losses

 

 

342,634

 

 

95,815

Deferred tax asset and liabilities

 

 

(2,336,506)

 

 

(590,952)

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(203,904)

 

 

(286,602)

Due from related party

 

 

225,654

 

 

—

Prepaids and other current assets

 

 

(861,888)

 

 

57,168

Accounts payable and accrued expenses

 

 

(161,975)

 

 

988,798

Operating lease liability

 

 

(76,823)

 

 

—

Deferred revenue

 

 

(119,413)

 

 

13,561

Income tax payable

 

 

63,855

 

 

—

Due to related party

 

 

(210,797)

 

 

181,010

Net cash used in operating activities

 

 

(2,815,248)

 

 

(523,436)

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Cash acquired in Business Combination – iDoc

 

 

29,123

 

 

—

Purchase of fixed assets

 

 

(50,507)

 

 

(2,690)

Net cash used in investing activities

 

 

(21,384)

 

 

(2,690)

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from Quantum Convertible Note, related party

 

 

2,700,000

 

 

—

Proceeds from September 2024 Convertible Note

 

 

2,000,000

 

 

—

Proceeds from reverse recapitalization with DHAC

 

 

1,323,362

 

 

—

Repayment on Extension Note

 

 

(365,750)

 

 

—

Repayment on factoring payable

 

 

(150,616)

 

 

—

Repayment on Additional Bridge Financing

 

 

(13,889)

 

 

—

Repayment on Encompass Purchase liability

 

 

(3,090)

 

 

—

Repayment on advances from related party

 

 

(47,800)

 

 

—

Repayment on note payable

 

 

(33,000)

 

 

—

Payment on financing lease liability

 

 

(363,982)

 

 

—

Proceeds from loan payable, related party

 

 

—

 

 

120,000

Proceeds from note payable

 

 

—

 

 

200,000

Proceeds from share repurchase liability

 

 

—

 

 

135,000

Net cash provided by financing activities

 

 

5,045,235

 

 

455,000

 

 

 

 

 

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

2,208,603

 

 

(71,126)

Cash and Cash Equivalents, Beginning of Period

 

 

118,734

 

 

230,664

CASH AND CASH EQUIVALENTS, END OF PERIOD

 

$

2,327,337

 

$

159,538

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

Cash paid for interest expense

 

$

6,738

 

$

—

Cash paid for taxes

 

$

3,092

 

$

—

Non-cash investing and financing activities:

 

 

 

 

 

 

Net liabilities acquired in reverse merger

 

$

(18,704,806)

 

$

—

Shares issued to DHAC Sponsor group for debt conversion

 

$

1,268,000

 

$

—

Shares issued to A.G.P. Underwriter for debt conversion

 

$

4,370,000

 

$

—

Shares issued to VSee debt holders for debt conversion

 

$

1,310,710

 

$

—

Fair value of shares issued in iDoc acquisition

 

$

68,907,052

 

$

—

Shares issued as principal payment of Additional Bridge Notes

 

$

60,346

 

$

—

Shares issued as principal payment of Exchange Note

 

$

664,790

 

$

—

Shares issued to acquire non-controlling interest in TAD

 

$

325,279

 

$

—

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241115789306/en/

Dave Gentry RedChip Companies, Inc. 1-407-644-4256 [e-mail]